Mahshid Imankhan

Mahshid Imankhan

Auto-generated profile, based on publicly available information

Mahshid Imankhan

Independent Researcher, 1514 Sheridan Rd NE apt 4014, Atlanta, Georgia, United States

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 August 2023 in International Journal of Endocrinology and Metabolism
Verified
Journal Article
Open access
PDF file
FSFahimeh Soheilipour
Fahimeh Soheilipour
NKNaghmeh Abbasi Kasbi
Naghmeh Abbasi Kasbi
MIMahshid Imankhan
Mahshid Imankhan
DEDelaram Eskandari
Delaram Eskandari
Context: Global reports have revealed a dramatic rise in the number of patients diagnosed with type 2 diabetes (T2DM) over the past three decades in all age groups, even in children and adolescents. The physiologic phenomenon of insulin resistance during puberty, as well as genetic and epigenetic factors, are implicated in this phenomenon. It seems that patients with early-onset T2DM experience a more aggressive clinical course; however, limited treatments available for these patients pose a challenge. This narrative review intends to scrutinize the micro- and macrovascular complications and treatments of patients with early-onset T2DM. Methods: The literature search was conducted in the PubMed database to identify all relevant original English articles published from the beginning of 2018 until January 2023. Results: Vascular complications, such as albuminuria, hypertension, cardiovascular diseases, and retinopathy, were seen to be more common in early-onset T2DM compared to type 1 diabetes. The odds ratio of vascular complications was higher in early-onset compared to late-onset T2DM. In children and adolescents with T2DM, the only approved medications included metformin, insulin, and glucagon-like peptide-1 agonists. Treatment of early-onset T2DM with metformin monotherapy cannot yield durable glycemic control, and most patients need early combination therapy. Conclusions: During the past years, the frequency of early-onset T2DM has been growing at an alarming rate. Vascular complications in these patients seem more aggressive and more challenging to control. Hence, further clinical trials should be conducted to develop novel therapeutic approaches and evaluate their long-term benefits in terms of glycemic control and preventing future complications.

28 July 2025 in Discover Oncology
Verified
Journal Article
Open access
PDF file
AAAlireza Azani
Alireza Azani
NANahal Aghajamal Avval
Nahal Aghajamal Avval
MMMohammad Saeed Soleimani Meigoli
Mohammad Saeed Soleimani Meigoli
MIMahshid Imankhan
Mahshid Imankhan
PAPouya Asgari
Pouya Asgari
MSMalihe Sharafi
Malihe Sharafi
Purpose This review investigates the complex association between type 2 diabetes mellitus (T2DM) and lung cancer, focusing on shared risk factors, molecular mechanisms, and clinical implications. We aim to quantify the impact of T2DM on lung cancer incidence, progression, and treatment response, and evaluate the role of glycemic control and antidiabetic therapies. Methods A narrative review was conducted following a targeted search of PubMed, Scopus, and Web of Science for published studies. Search terms included “type 2 diabetes mellitus,” “lung cancer,” “non-small cell lung cancer,” “hyperglycemia,” “insulin resistance,” and relevant synonyms. Inclusion criteria were original research articles, meta-analyses, and clinical trials involving human subjects that explored epidemiological associations, molecular mechanisms, pharmacologic interventions, or prognostic implications of T2DM in lung cancer. Studies focusing solely on type 1 diabetes, animal models, or non-English language were excluded. Key findings were synthesized to provide mechanistic insights and clinical relevance. Results Epidemiological evidence indicates a 20–48% increased relative risk of lung cancer in individuals with T2DM, with incidence rates reaching 125 per 100,000 in diabetics versus 85 per 100,000 in non-diabetics. Shared risk factors include obesity, smoking, and physical inactivity. Molecular pathways such as K-Ras and PI3K/Akt activation, IGF-1R overexpression, and hyperglycemia-induced oxidative stress promote tumorigenesis and metastasis. Metformin is associated with reduced lung cancer incidence and improved progression-free survival (58% vs. 37% at 2 years). Pioglitazone and DPP4 inhibitors show potential benefits, though clinical evidence remains mixed. Conclusion T2DM significantly influences lung cancer biology and prognosis. Integrating glycemic control with cancer therapy—particularly metformin and EGFR-TKI combinations—offers promising avenues for improving outcomes. Future research should focus on biomarker-driven stratification and targeted therapeutic strategies tailored to diabetic lung cancer patients.

23 September 2023 in Journal of Parathyroid Disease
Verified
Journal Article
Open access
PDF file
AAAli Azarpey
Ali Azarpey
MIMahshid Imankhan
Mahshid Imankhan
SNSina Neshat
Sina Neshat
Bariatric surgery is a type of weight loss surgery that is commonly used to treat obesity. However, this surgery can also affect the body’s calcium and PTH metabolism, leading to the development of secondary hyperparathyroidism (SHPT). Several factors contribute to the development of SHPT after bariatric surgery. Malabsorption of calcium due to reduced intestinal surface area, decreased intake of calcium-rich foods, and altered vitamin D metabolism play a significant role. The loss of weight-bearing adipose tissue can also disrupt the balance between bone formation and resorption, leading to increased bone turnover and calcium release from the skeleton. The management of SHPT after bariatric surgery involves a multidisciplinary approach. Calcium and vitamin D supplementation is essential to correct deficiency and maintain bone health. However, achieving optimal calcium and vitamin D levels can be challenging due to malabsorption issues and the need for higher supplementation doses. In some cases, pharmacological interventions such as calcimimetics or PTH analogs may be required to control PTH levels. However, these medications should be used cautiously due to limited data on their safety and efficacy in the bariatric surgery population. Prevention of SHPT is an important aspect of managing patients undergoing bariatric surgery. Nutritional counseling and regular monitoring of calcium, vitamin D, and PTH levels can help identify and address deficiencies early on. Additionally, using procedures that preserve the duodenum and proximal jejunum, such as duodenal switch or biliopancreatic diversion with duodenal switch, may reduce the risk of developing SHPT.

20 November 2023 in Journal of Nephropharmacology
Verified
Journal Article
Open access
PDF file
SZSamaneh Zandifar
Samaneh Zandifar
MIMahshid Imankhan
Mahshid Imankhan
PDPadideh Daneii
Padideh Daneii
AAAli Azarpey
Ali Azarpey
LALeila Alem
Leila Alem
Immune checkpoint inhibitors work by blocking the "checkpoint" mechanism that tumors use to hide from the immune system, therefore also weakening the immune system. Consequently, checkpoint inhibitors can cause autoimmune reactions, resulting in adverse effects. Prompt identification and management of adverse effects are critical for patients under checkpoint inhibitor therapy due to the potential severity and unpredictability of these immune-related adverse events.

23 September 2023 in Journal of Preventive Epidemiology
Verified
Journal Article
Open access
ABAzar Baradaran
Azar Baradaran
PDPadideh Daneii
Padideh Daneii
MIMahshid Imankhan
Mahshid Imankhan
MMMahsa Motieian
Mahsa Motieian
SNSina Neshat
Sina Neshat
Collapsing glomerulopathy is a rare and serious disease that is characterized by a rapid deterioration of kidney function and heavy proteinuria. This disease is a variant of focal segmental glomerulosclerosis (FSGS). The disease is more serious than other types of FSGS, with high risks of renal failure and poor prognosis. Collapsing glomerulopathy is often resistant to immunosuppressive therapy and can rapidly result in renal failure, making diagnosing and managing this disease an enormous challenge.

23 September 2023 in Journal of Parathyroid Disease
Verified
Journal Article
Open access
PDF file
ABAzar Baradaran
Azar Baradaran
PDPadideh Daneii
Padideh Daneii
MIMahshid Imankhan
Mahshid Imankhan
MMMahsa Motieian
Mahsa Motieian
SNSina Neshat
Sina Neshat
Prospects in parathyroid diseases involve a multidisciplinary approach that combines research, clinical practice, and patient-centered care to improve understanding, diagnosis, and treatment outcomes for individuals with these conditions. Accordingly, further advancements in genetics, biomarkers, imaging, targeted therapies, non-surgical treatments, and personalized medicine can potentially revolutionize diagnosing, treating, and managing parathyroid diseases.